Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide

Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV

(2021) I-Wen Chen et al.   Infectious Diseases and Therapy

Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection

(2020) Jennifer E Hibma et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial

(2020) Kelly E Dooley et al.   Lancet HIV

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention

(2020) A T Podany et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis

(2019) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

(2019) Maddalena Cerrone et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug–Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine

(2018) Kristina M Brooks et al.   CLINICAL INFECTIOUS DISEASES

Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial

(2017) Anani Badje et al.   Lancet Global Health

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

(2016) Manuel Tsiang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention

(2015) Anthony T. Podany et al.   CLINICAL INFECTIOUS DISEASES

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial

(2014) Molebogeng X Rangaka et al.   LANCET

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

(2013) Peter J. Ruane et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers

(2013) M. Weiner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort

(2009) Jonathan E Golub et al.   AIDS

Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?

(2008) Alan Winston et al.   Current Opinion in HIV and AIDS